Matheson advised Trinity Biotech plc, clinical diagnostics company, on its acquisition of Epicapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer.
Matheson advised Trinity Biotech plc, clinical diagnostics company, on its acquisition of Epicapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer.